characteristics of first dose COVID-19 vaccine breakthrough
Title: COVID-19 hospital admissions and deaths post BNT162b2 and ChAdOx1 vaccinations: National prospective cohort study of 2.57 million people in Scotland
Authors: Utkarsh Agrawal, Srinivasa Vittal Katikireddi, Colin McCowan, Rachel H. Mulholland, Amaya Azcoaga-Lorenzo, Sarah Amele, et. al.
Data Sorce: Early Pandemic Evaluation and Enhanced Surveillance of COVID-19 (EAVE II). Available at http://dx.doi.org/10.1136/bmjopen-2020-039097
This analysis is part of the Early Assessment of COVID-19 epidemiology and Vaccine/anti-viral Effectiveness (EAVE II) study. EAVE II is funded by the Medical Research Council (MR/R008345/1) with the support of BREATHE - The Health Data Research Hub for Respiratory Health [MC_PC_19004], which is funded through the UK Research and Innovation Industrial Strategy Challenge Fund and delivered through Health Data Research UK. Additional support has been provided through the Scottish Government DG Health and Social Care.